Human Genome Sciences, Inc. and GlaxoSmithKline Announce Publication of BLISS-52 Phase 3 Study Results for BENLYSTA(R) in The Lancet

ROCKVILLE, Md. & LONDON--(BUSINESS WIRE)--Human Genome Sciences, Inc. (Nasdaq: HGSI) and GlaxoSmithKline PLC (GSK) today announced publication of the BLISS-52 study of BENLYSTA® (belimumab) in autoantibody-positive patients with active systemic lupus erythematosus (SLE) in The Lancet (http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)61354-2/abstract).